Leukocyte recruitment is pivotal for the initiation and perpetuation of inflammatory bowel disease (IBD) and controlled by the specificity and interactions of chemokines and adhesion molecules. Interactions of the adhesion molecules a4b7-integrin and mucosal addressin cell-adhesion molecule-1 (MAdCAM-1) promote the accumulation of pathogenic T-cell populations in the inflamed intestine. We aimed to elucidate the significance of b7-integrin expression on innate immune cells for the pathogenesis of IBD. We demonstrate that b7-integrin deficiency protects recombination-activating gene-2 (RAG-2)-deficient mice from dextran sodium sulfate (DSS)-induced colitis and coincides with decreased numbers of colonic effector monocytes. We also show that b7-integrin is expressed on most CD11b þ CD64 low Ly6C þ bone marrow progenitors and contributes to colonic recruitment of these proinflammatory monocytes. Importantly, adoptive transfer of CD115 þ wild-type (WT) monocytes partially restored the susceptibility of RAG-2/b7-integrin double-deficient mice to DSS-induced colitis, thereby demonstrating the functional importance of b7-integrin-expressing monocytes for the development of DSS colitis. We also reveal that genetic ablation of MAdCAM-1 ameliorates experimental colitis in RAG-2-deficient mice as well. In summary, we demonstrate a previously unknown role of a4b7-integrin-MAdCAM-1 interactions as drivers of colitis by directing inflammatory monocytes into the colon.
INTRODUCTION
The recirculation of leukocytes is regulated by migration pathways that are secured by the specificity and interactions of chemokines and adhesion molecules. 1 Regulated expression and activation of these molecules helps to initiate and terminate physiologic inflammatory processes. Inappropriate expression, however, can cause a massive and destructive infiltration of leukocytes, leading to tissue inflammation and chronic manifestations. An abnormal cell influx into the inflamed intestine is a prominent histopathologic feature and is fundamental to the development and perpetuation of inflammatory bowel disease (IBD). 2 Hence, there is a great need to better understand leukocyte trafficking, which is a major target for IBD therapy.
The lymphocyte adhesion molecule b7-integrin directs the migration of lymphocytes into the gut-associated lymphoid tissue. 3, 4 Integrins are heterodimeric transmembrane cell adhesion receptors consisting of noncovalently associated a and b chains. The b7-integrin chain combines with either the a4 or the aE (CD103) chain. Whereas aEb7-integrin facilitates the retention of lymphocytes in the gut epithelium through binding to E-cadherin, a4b7-integrin directs the migration of lymphocytes into the small intestine and into the mesenteric lymph nodes mainly via interaction with its endothelial ligand mucosal addressin cell-adhesion molecule-1 (MAdCAM-1). MAdCAM-1 is a cell-surface, immunoglobulin-like adhesion molecule that belongs to the immunoglobulin superfamily. 5 It is predominantly expressed on high endothelial venules of the gut-associated lymphoid tissue and on venules at chronically inflamed sites. 6 Similar to a4b7-integrin, L-selectin is able to adhere to MAdCAM-1, 7 and also to carbohydrate moieties presented on glycoprotein scaffolds. 8 A further ligand for a4b7-integrin is the vascular cell adhesion molecule-1, although this interaction is reported to require a higher state of integrin activation in comparison with MAdCAM-1 binding. 9 This diversity of receptor-ligand interactions, which is made even more complicated by redundant mechanisms of leukocyte trafficking, makes unraveling of the physiologic roles of the individual adhesion molecules particularly difficult.
A role for a4b7-MAdCAM-1 interactions in directing lymphocytes to the intestine is widely accepted and inflammation of the intestine is associated with an enhanced expression of MAdCAM-1 and an increased density of a4b7-integrinpositive cells in the colonic lamina propria of both experimental animals and humans. 4, 6, 10 Moreover, vedolizumab, a humanized monoclonal antibody that specifically targets the a4b7 heterodimer, is effective in treating IBD. 11 Previously, we have shown that the onset of colitis was delayed significantly in recipients of T cells from b7-integrin-deficient (b7-integrin D/D or b7 D/D) donors in the CD4 þ CD45RB high model of T-cell transfer colitis, 12 which indicates the importance of b7-integrin on effector T cells in the induction and perpetuation of IBD. To extend this study, we chose to analyze the role of b7-integrin for innate immune cells in a model where lymphocytes are not essential for colonic inflammation. Oral administration of dextran sodium sulfate (DSS) in the drinking water of mice is a widely used IBD model. 13, 14 It causes an acute and chronic colitis in mice with some morphological changes similar to human ulcerative colitis, including an increased expression of adhesion molecules, infiltration of leukocytes, production of inflammatory mediators, and gut injury. 14 It is a relevant model for the translation of data from mice to humans, as it has been shown to respond to drugs used in IBD therapy. 15 DSS acts mainly by breaching the intestinal barrier function, thereby exposing subepithelial immune cells to commensal bacteria and is relatively independent of lymphocyte actions, as mice lacking T cells, B cells, and NK cells can still develop colitis in response to DSS. 16, 17 By a comparative analysis of b7-integrin D/D mice, wild-type (WT) mice, RAG-2/b7-integrin double-deficient mice, RAG-2-deficient (RAG-2 D/D) mice, and RAG-2/ MAdCAM-1 double-deficient mice in the DSS model, we have been able to point out the importance of a4b7-MAdCAM-1 interactions for innate immune cells in the induction and perpetuation of IBD.
RESULTS

b7-Integrin promotes acute and chronic DSS-induced colitis
To assess the impact of b7-integrin on the development of acute colitis, WT and b7 integrin D/D mice were exposed to 3% DSS in the drinking water. DSS treatment induced a substantial weight loss in WT mice, which was less pronounced in b7-integrin D/D mice ( Figure 1a) . In addition, compared with b7-integrin D/D mice, WT mice exhibited an elevated cumulative disease activity index (DAI) (Figure 1b ). All vehicle control (i.e. regular water) mice were negative for weight loss and are therefore not graphed. Moreover, the reduction in colon length, which is a marker of intestinal inflammation, was significantly less pronounced in DSS-treated b7-integrin D/D mice, when compared with equally treated WT mice ( Figure 1c) . As expected, DSS treatment induced a severe inflammatory response in WT mice, with an almost complete loss of crypts, dense infiltrates of leukocytes in both mucosa and submucosa, and thickening of the bowel wall. By contrast, the infiltrates in DSS-treated b7-integrin D/D mice were much smaller and less tissue damage was observed (Figure 1d) . Histological scoring for inflammatory infiltrates and epithelial damage confirmed these findings as significant (Figure 1e ). We also studied the impact of b7-integrin on the development of chronic DSS colitis by subjecting b7-integrin D/D mice and WT mice to three 7-day cycles of DSS administration, each followed by 14 days of regular drinking water. DSS-treated b7-integrin D/D mice exhibited a reduced loss in body weight (Figure 1f) , and an improved stool consistency and diminished fecal occult blood, when compared with DSS-treated WT mice. The clinically observed attenuation of chronic intestinal inflammation in b7-integrin D/D mice was corroborated by histopathologic evaluation that featured reduced numbers of mucosal erosions, smaller ulcerations, lower hyperplasia, and decreased inflammatory infiltration compared with WT mice, resulting in a significantly decreased cumulative histological score ( Figure 1g ). Certain cytokines and proinflammatory mediators contribute to the pathogenicity of human IBD and are reportedly increased in DSS-induced colitis. 18 We therefore investigated whether the attenuation in acute DSS-induced colitis, which was observed in b7-integrin D/D mice, was reflected by changes in the expression levels of some of these mediators in colonic tissue homogenates or serum samples. Upon DSS treatment, all mice showed a significant enhancement in the colonic mRNA levels for tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), interferon-g (IFN-g), tumor growth factor-b (TGF-b), C-C chemokine ligand-2 (CCL-2), and inducible nitric oxide reductase (iNOS). Interestingly, b7-integrin D/D mice exhibited a reduced trend in the expression of the proinflammatory iNOS, CCL-2, IL-6, and TNF-a (Figure 2a) , the latter was confirmed as significant when measured as protein level in serum (Figure 2b) . By contrast, the expression of the anti-inflammatory cytokine TGF-b appeared to be increased (Figure 2a) . Figure 1D) . Further delineation of the CD11b þ cell population revealed that although there was no significant difference in the number of immigrated
þ cells, which have been described as inflammatory monocytes, 19 was reduced in DSS-treated b7-integrin D/D mice when compared with equally treated WT mice (Figure 3c ).
Aggravation of DSS-induced colitis by b7-integrin is mediated by cells of the innate immune system
Because it has been shown that lymphocytes may contribute to the outcome of DSS-induced colitis, 20, 21 we compared the outcome of DSS-induced colitis in RAG-2 D/D and RAG-2/b7-integrin double-deficient mice, which lack mature T and B cells. 22 As RAG-2 D/D mice responded to DSS treatment with even more severe colitis compared with WT mice, we reduced the DSS dosage (2.5% DSS) to avoid mortality. Interestingly, when T and B cells were absent, the protective effect of the b7-integrin deficiency was even more pronounced. As shown in Figure 4 , DSS administration to RAG-2 D/D mice was associated with significant weight loss ( Figure 4a ) and clinical changes including diarrhea and occult fecal blood, resulting in a strongly increased cumulative DAI score (Figure 4b) , whereas additional b7-integrin deficiency resulted in a significant amelioration of DSS colitis. Consistently, DSS-treated RAG-2 D/D mice showed a more severe reduction in colon length compared with DSS-treated RAG-2/b7 integrin doubledeficient mice (Figure 4c) . Moreover, DSS-treated RAG-2 D/D mice exhibited more severe histopathology, accompanied by crypt destruction, mucosal ulcers, and erosions in the mucosal tissue, compared with the equally treated RAG-2/b7-integrin double-deficient mice (Figure 4d) , which was statistically confirmed by histological scoring (Figure 4e) . Analysis for inflammatory markers revealed that exposure of RAG-2 D/D mice to DSS resulted in enhanced colonic mRNA levels for IL-6, CCL-2, and iNOS, whereas in line with their immune-deficient status, we detected no induction of IFN-g. Compared with DSS-treated RAG-2 D/D mice, equally treated RAG-2/b7-integrin double-deficient mice exhibited an attenuation in the CCL-2 increase, measured as Supplementary Figure 2) .
Moreover, quantification of CAE þ cells on colon sections of DSS-treated RAG-2/b7-integrin double-deficient and RAG-2 D/D mice showed that loss of b7-integrin significantly attenuates myeloid cell infiltration in response to DSS (Figure 4f) . Flow cytometric analysis of colonic cells of healthy and colitic animals revealed a decrease in the fraction of inflammatory monocytes
We also assessed the role of b7-integrin on innate immune cells in the T-cell transfer model of chronic colitis. 2 This model is based on a disturbed T-cell homeostasis, which is caused by the adoptive transfer of CD4 þ CD45RB high T cells (naïve T cells) from healthy WT mice into lymphopenic recipients and results in pancolitis and small bowel inflammation at 5-8 weeks following T-cell transfer. In the initial stage of this model, RAG-2/b7-integrin double-deficient recipient mice exhibited an aggravated state of health (up to week 3; Figure 5a , b). However, there was no difference between the two mouse strains in the outcome of colitis 9 weeks after the cell transfer (Figure 5a, c) , although we observed an increased number of inflammatory monocytes in the small intestine of colitic RAG-2 D/D mice, which was attenuated in RAG-2/b7-integrin double-deficient mice (Figure 5d ). Figure 3) . At 16 h after transfer, we monitored CFSE þ
CD11b
þ Ly6C þ inflammatory monocytes that had arrived in different organs. There was no difference in the migration efficiency of CFSE þ b7-integrin D/D or WT cells into the spleen, mesenteric lymph nodes, and peripheral lymph nodes (Figure 6b and data not shown) . However, we detected a marked reduction in the number of (Figure 6b, c) .
Next, we assessed whether transfer of WT monocytes would aggravate the DSS-induced colitis in RAG-2/b7-integrin double-deficient mice. To this end, we administered CD115-enriched bone marrow cells from WT mice intravenously into RAG-2/b7-integrin double-deficient mice on the second day of DSS treatment (Figure 6d-f) . The subsequent development of colitis was assessed in comparison with that found in DSS-treated RAG-2/b7-integrin double-deficient mice that had received an equal number of b7-integrin D/D CD115-enriched bone marrow cells and DSS-treated RAG-2/ b7-integrin double-deficient and DSS-treated RAG-2 D/D mice without cell injection. Transfer of WT monocytes significantly increased DSS-induced colitis in RAG-2/b7-integrin doubledeficient mice, as evidenced by enhanced weight loss ( Figure 6d ) and cumulative DAI (Figure 6e) , and more severe histopathology (Figure 6f) , thereby restoring at least part of the susceptibility to colitis seen in RAG-2 D/D mice. DSStreated RAG-2/b7-integrin double-deficient mice that had received an equal number of b7-integrin D/D CD115-enriched bone marrow cells also exhibited a trend towards aggravation of colitis, which was not however significant.
Amelioration of DSS colitis in RAG-2/MAdCAM-1 double-deficient mice
b7-Integrin directs the migration of lymphocytes into the gut-associated lymphoid tissue mainly via its endothelial ligand MAdCAM-1. 4, 26 To find out whether MAdCAM-1 also mediates the lymphocyte-independent role of b7-integrin in DSS colitis, we studied the outcome of DSS colitis in RAG-2/ MAdCAM-1 double-deficient mice. Consistent with this hypothesis, body weight loss ( Figure 7a ) and cumulative DAI (not shown) were markedly attenuated in DSS-treated RAG-2/MAdCAM-1 double-deficient mice relative to DSStreated RAG-2 deficient mice. Histological examination and scoring of colon sections from DSS-treated RAG-2/MAdCAM-1 double-deficient mice confirmed the reduced severity of inflammation when compared with DSS-treated RAG-2 D/D mice (Figure 7b ).
DISCUSSION
Preventing leukocyte recruitment to inflammatory sites by selectively interfering with leukocyte-endothelial interactions represents a promising strategy for IBD treatment. Recent clinical trials have shown that immunoneutralizing a4b7-integrin with vedolizumab, b7-integrin with etrolizumab, or MAdCAM-1 with PF-00547659 significantly improves IBD. 11 However, the exact mechanism of action and the types of immune cells targeted by these anti-adhesion therapies have not yet been defined sufficiently. Up to now, the beneficial effects of a b7-integrin blockage have been attributed to a blocking of the access of circulating T cells to the inflamed intestine. 6, 12, [27] [28] [29] However, in addition to its expression on lymphocytes, a4b7-integrin is found on the surface of innate immune cells as well, and defects in innate immunity may be central to the pathogenesis of IBD. 30 Interestingly, we have Moreover, two recent publications demonstrate that a4b7-integrin directs the migration of a certain set of premucosal DC progenitors from the bone marrow to the intestinal mucosa 32 and is required for the differentiation of intestinal CD11c þ DCs with tolerogenic potential. 33 Herein, we show that b7-integrin D/D mice exhibited attenuation in acute and chronic DSS-induced colitis. Amelioration of DSS colitis in b7-integrin D/D mice was accompanied by a decreased influx of myeloid cells. The number of inflammatory monocytes in particular appeared to be reduced when compared with equally treated WT mice. Macrophage infiltration is a characteristic feature of IBD and is presumed to have a key role in IBD pathogenesis and DSS-induced colitis. 34, 35 DSS has been shown to promote the recruitment of F4/80 þ CD11b þ CCR2 þ Ly6C high inflammatory monocytes into the colon. 36 Moreover, microsphere-induced macrophage depletion, 37 neutralization of colony-stimulating factor-1, which is necessary for macrophage development, 38 or ablation of Ly6C high monocytes by anti-MC21 (CCR2) antibodies, 39 has been shown to alleviate DSS-induced colitis. Most of the TNF-a-or iNOS-producing cells in the inflamed colon of DSS-treated mice are reportedly monocytes or macrophages. The enzyme iNOS is essential for the generation of NO. It has also been detected in inflammatory infiltrates of the lamina propria and colonic epithelial cells in human IBD. 40, 41 The pathogenic involvement of NO in DSS-induced colitis was evidenced by the fact that selective inhibitors of iNOS suppressed DSS-induced colonic inflammation. 20 ,42 Accordingly, we found a trend towards a reduced iNOS expression in the colon of DSS-treated b7-integrin D/D mice when compared with equally treated WT mice. These results suggest that b7-integrin deficiency ameliorates DSS-induced colitis by inhibition of the colonic immigration of proinflammatory monocytes and macrophages, thereby decreasing the production of proinflammatory mediators and inflammatory responses. DSS-induced colitis starts with disruption of the epithelium, followed by the activation of macrophages and neutrophils, and does not depend on adaptive immunity. 16 However, T-cell responses in this model were shown to aggravate or ameliorate the inflammatory response in the presence of an intact innate and adaptive immunity and are especially involved in chronic DSS-induced colitis, 43, 44 which was ameliorated by b7-integrin deficiency. Whereas the T-cell response in the acute stage of DSS-induced colitis was described as a polarized Th1 response, the later and more chronic inflammation was characterized by a mixed Th1/ Th2 response. 44 Furthermore, an involvement of CCR4-expressing effector T cells was reported in the development of DSS-induced colitis, 45 and adoptive transfer of primed T cells from DSS-treated mice was shown to aggravate DSS-induced colitis. 46 By contrast, lymphopenic mice were shown to be more susceptible to DSS-induced colitis, 16, 20 indicating a protective role of lymphocytes in the inflammatory process, and deletion of FoxP3 þ regulatory T cell (Treg) in mice with an intact immune system caused an aggravation of DSS-induced colitis, 47 whereas CD25 þ Treg suppressed the inflammatory process in a TGFb-dependent manner. 48 The ameliorated DSS-induced colitis in b7-integrin D/D mice with an intact innate and adaptive immune system was accompanied by shifts in the number of colonic lymphocytes. To rule out their contribution to the inflammatory process, we analyzed the role of b7-integrin in the pathogenesis of DSS colitis in lymphopenic RAG-2 mice. When compared with the respective WT mice, DSS-treated mice as well as untreated RAG-2 mice exhibited higher numbers of colonic inflammatory monocytes, which suggests a contribution of endogenous T cells to the control of colonic monocyte homeostasis and recruitment. In line with data from the literature, 16, 20 RAG-2 D/D mice were more susceptible to DSS colitis compared with WT mice, most probably because of the absence of protective Tregs. 2, 47, 48 Interestingly, colitis expression was much better tolerated in RAG-2/b7-integrin double-deficient mice compared with that in RAG-2 D/D mice, again accompanied by attenuated numbers of inflammatory monocytes and decreased expression of proinflammatory cytokines in the colon. Hence, the development of intestinal pathology in RAG-2 D/D mice appears to be a b7-integrin-mediated myeloid cell autonomous process, which does not depend on myeloid cell/lymphocyte interactions.
Of course, we cannot exclude that, in addition to inflammatory monocytes, other myeloid cell types contribute to the proinflammatory action of b7-integrin in DSS-induced colitis.
Although not significant, we observed a trend towards a reduction in the numbers of colonic granulocytes in b7-integrin D/D mice, when compared with the respective WTs. These can include mast cells, basophils, neutrophils, and eosinophils. Depending on the experimental model of colitis used, all of these cell types have the potential to influence the degree of colitis in a pro-or anti-inflammatory manner. Basophils as well as mast cells express b7-integrin. Recently, basophils were shown to exert beneficial effects in T-cell-mediated colitis, 49 whereas the involvement of mast cells in DSS-induced colitis, at least in immunocompetent mice, does not appear to be crucial. 50 As neutrophils do not express a4b7-integrin on their surface, differences in the immigration of neutrophils resulting from b7-integrin deficiency would be secondary effects. Moreover, in the context of DSS-induced colitis, the role of colonic neutrophils seems to be beneficial in supporting antimicrobial defense and resolution of colitis. 51 Previously, we have shown, that a4b7-integrin on eosinophils is crucial for eotaxin-1-mediated eosinophil recruitment into the small intestine, 52 whereas eosinophil accumulation in the colon in the context of DSS colitis can occur independently of a4b7-integrin. 53 Although eosinophils have recently been described as promoters of chronic inflammation and tissue damage in chronic T-cell-dependent colitis, 54 they have been shown to exert protective effects in DSS-induced colitis. 55 Intestinal macrophages develop from constantly arriving Ly6C þ CX3CR1 int blood monocytes. 23 In the healthy mouse mucosa, these monocytes are actively conditioned, as reported recently, upon sensing of IL-10, 56 to become nonmigratory and noninflammatory resident Ly6C þ CX3CR1 hi macrophages. 39, 57, 58 Acute inflammation, however, results in an increased immigration and impaired conditioning of these effector monocytes, thereby giving rise to CX3CR1 int monocytes with proinflammatory, disease-promoting capacity. 56, 57 Herein, we have shown that b7-integrin is expressed on CD11b þ CD64 low Ly6C þ monocytes, isolated from the bone marrow, and that b7-integrin promotes the recruitment of these cells into the inflamed colon. Moreover, adoptive transfer of bone marrow-derived b7-integrin-expressing monocytes into DSS-treated RAG-2/b7-integrin double-deficient mice was sufficient to increase disease susceptibility. Therefore, it is most likely that the protective effects of a b7-integrin deficiency on DSS colitis result from a disturbed colonic immigration of effector monocytes. Hence, the actions of b7-integrin are more complex than originally assumed. As the intestinal homing molecule on lymphocytes, it contributes to immune defense, 6 T-and B-cell tolerance, 59, 60 and T-cell-dependent colitis. 6, 12, 28 We have shown herein that b7-integrin on inflammatory monocytes promotes colitis in the T-cell-independent DSS model. Therefore, the beneficial effects of a vedolizumab treatment in human IBD 11 are probably mediated not only by blocking the b7-integrin-dependent access of circulating effector lymphocytes to the inflamed intestine but also by reducing the b7-integrin-dependent influx of inflammatory monocytes. Moreover, b7-integrin was shown to be involved in the intestinal recruitment of certain DC progenitors 31, 32 and required for the anti-inflammatory actions of tolerogenic DC in experimental T-cell colitis. 33 The latter data from Villablanca et al., 33 which show that mice lacking b7-integrin in the innate immune compartment are more susceptible to T-cell-mediated colitis, are not in contrast to our findings. Also in our hands RAG-2/b7-integrin double-deficient mice displayed an aggravated state of health in the initial stage of this model up to 3 weeks, when compared with the respective RAG-2 deficient mice. However, the animals recovered and we have noted no difference in disease severity between the two mouse strains in the later stages of disease (after 9 weeks), when T-cell-mediated colitis is usually monitored. 61 Villablanca et al. 33 attribute their results to the reduced immigration of tolerogenic mononuclear phagocytes (ALDE þ ) in the mesenteric lymph nodes and small intestine of RAG2/b7-integrin double-deficient mice, when compared with the respective RAG-2-deficient mice, in the early stage of disease. However, our results point to a minor function of these cells in the later stages of T-cell-mediated colitis. Although we have detected decreased numbers of inflammatory monocytes in the small intestine of RAG2/b7-integrin D/D mice (in contrast to the respective RAG-2-deficient mice), there was no difference in the outcome of colitis. These findings hint at a minor function of tolerogenic and inflammatory monocytes in T-cell-mediated colitis.
Increased MAdCAM-1 expression on colonic vascular endothelial cells contributes to the infiltration of a4b7-integrin-expressing effector T lymphocytes into inflamed gut lesions 4 and treatment with monoclonal MAdCAM-1-specific antibodies has been shown to ameliorate IBD in different animal models of colitis, a result that has so far been attributed to the blocked recruitment of lymphocytes. 6, 10 Here, we have shown that genetic deletion of MAdCAM-1 in RAG-2 D/D mice resulted in a similar protection against DSS-induced inflammation compared with RAG-2/b7-integrin doubledeficient mice. This finding suggests an additional function of MAdCAM-1 in promoting lymphocyte-independent colitis, by directing b7-integrin-expressing innate immune cells to the inflamed intestine.
In conclusion, we have demonstrated that beyond its role in lymphocyte trafficking, b7-integrin exacerbates colitis by promoting the accumulation of effector monocytes within the inflamed intestine, most probably mediated via interaction with MAdCAM-1. Thus, our study contributes to a better understanding of the cell migration pathways associated with the pathogenesis of experimental colitis and identifies inflammatory monocytes as a potential target for specific antiadhesive drugs. high cells in phosphate-buffered saline were injected intraperitoneally into RAG-2 D/D or RAG-2/b7-integrin double-deficient mice. Body weights and fecal status were followed and recorded weekly from the time of injection. Mice were killed at 9 weeks following adoptive transfer, by which time the recipients had lost B10% of their initial body weight.
The DAI was assessed using a validated scoring system, as described previously by Osman et al. 62 Each animal was examined once a day and received a score on a scale of 0-4 for weight loss, stool consistency, and the presence of fecal blood. These features were averaged for each mouse and each group to calculate the DAI. The scores were defined as follows: weight loss-0 ¼ body weight increased or remained within 1% of the baseline; 1 ¼ 1-5% weight loss; 2 ¼ 5-15% weight loss; 3 ¼ 15-20% weight loss; and 4 ¼ 420% weight loss. Stool consistency-0 ¼ normal stools; 2 ¼ loose stools; and 4 ¼ diarrhea. The HemoCare test (Care Diagnostica, Voerde, Germany) was used to screen for occult blood in the stool and was scored as follows: 0 ¼ negative test, no blood; 2 ¼ positive test, moderate blood; and 4 ¼ gross bleeding from the anus.
Histological scoring. The 4 mm paraffin sections were serially cut, thereby dividing the Swiss-rolled colon into four levels of equal size, mounted onto glass slides, and deparaffinized. One section from each of the four levels was stained with hematoxylin and eosin by the Core Facility (IZKF) of the RWTH Aachen University. Blinded histological scoring was performed using a standard microscope, based on the method described previously. 63 The naphthol-AS-D-chloroacetate esterase (CAE) staining was performed for each animal on one section from the middle of the colon, according to standard procedures. The number of positive red-stained leukocytes from 10 fields of vision (original magnification, Â 40) was counted and averaged for each animal.
Quantification of cytokines and chemokines. Total RNA isolations from the distal part of the colon and cDNA synthesis were performed as described previously. 63 Real-time polymerase chain reaction was performed in duplicate in a total volume of 25 ml, on a 7300 RT-PCR System with 7000 System SDS Software Version 1.2.3 (Applied Bioscience, Darmstadt, Germany) using the qPCR Master Mix for SYBR Green I (Eurogentec, Cologne, Germany) and specific primers for: glyceraldehyde-3-phosphate-dehydrogenase-sense, Serum from cardiac blood was separated by centrifugation and kept at À 80 1C until analysis. Fifty micrograms of colon tissue were homogenized in the lysis buffer (10 mM HEPES/2 mM EDTA/5 mM DTT/1 mM Pefablock; Sigma-Aldrich, Taufkirchen, Germany) containing Protease Inhibitor Cocktail (Roche, Mannheim, Germany). The homogenates were centrifuged at 4,000 g for 10 min, and the supernatants were stored at À 80 1C for further analysis. Protein concentrations were quantified by a Bradford assay (BioRad, Hercules, CA).TNF-a and CCL-2 were determined with commercial DuoSet ELISA TNFa and MCP-1 Kits (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions.
Flow cytometry. Cell isolation and surface staining were performed as described previously 59 using the following antibody conjugates: anti-CD8-PB (53-6.7), anti-CD11b-PB (M1/70), anti-CD11c-APC (N418), anti-CD11c-PE-Cy7 (N418), anti-CD115-bio (AFS98), anti-F4/80-APC (BM8), anti-Gr1-FITC (Ly6G/C, RB6-8C5), anti-Gr1-PE-Cy5
(Ly6G/C, RB6-8C5), anti-PDCA-1-APC (eBio128c1), Str.-PE-Cy7 (all from eBioscience), anti-CD3-FITC/145-2C11), anti-CD4-APC (RM4-5), anti-C19-APC (1D3), anti-CD45-APC-Cy7 (30-F11), Ly6C-PerCp-Cy5.5 (AL21), anti-Ly6G-FITC (1A8), anti-b7-PE (M293) (all from BD Bioscience), anti-mouse F4/80-RPE (C1:A3-1) (from Serotec, Oxford, UK), and anti-mouse CD64-Brillinat Violet 421 (X54-5/7.1) (BioLegend, Fell, Germany). Cells were measured on a FACS Canto II (BD Bioscience). Inflammatory monocytes were defined as CD45 þ Ly6G Figures 3, 4 and Figure 5 , and as a new monoclonal antibody was available, as CD45 þ Ly6C þ (clone AL-21) CD11b þ cells in Figure 6 . Data were analyzed by the FlowJo 8.7.3 software (Tree Star, Ashland, OR).
Isolation, CFSE labeling, and adoptive transfer of bone marrow monocytes. CD115 þ bone marrow cells were purified by MACS using an anti-CD115 biotinylated antibody, followed by antibiotin microbeads (Miltenyi Biotec GmbH) according to the manufacturer's instructions. Purity of the enriched cell fraction was controlled by staining a sample of these cells with an antibody cocktail containing anti-CD45 and anti-Ly6C and was consistently 95% (shown as representative FACS plot in Supplementary Figure 3) . The cells were resuspended in an appropriate volume of sterile phosphate-buffered saline allowing for 2 Â 10 6 cells per tail vein injection and were transferred once, on the second day of DSS treatment.
For CFSE labeling, 5 Â 10 7 cells were incubated in 5 ml RPMI þ 25 mM HEPES for 30 min at 37 1C. Thereafter, the cells were stained with 1 mM CFSE for 10 min at 37 1C in the dark. The labeling reaction was stopped by washing with phosphate-buffered saline/0.5% bovine serum albumin.
Data analysis. Statistical analyses were performed with GraphPad Prism software (version 5; GraphPad, La Jolla, CA).
Data are presented as mean ± s.e.m., unless otherwise indicated. The specific statistical tests are indicated in the respective figure legends.
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